Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection.

Animals Antibodies, Monoclonal / immunology Cricetinae Orthohantavirus / pathogenicity Hantavirus Infections / genetics Humans Survival Analysis
Andes virus Bunyavirus Sin Nombre virus antibody cross-reactivity hantavirus infection

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
04 05 2021
Historique:
received: 20 10 2020
revised: 17 03 2021
accepted: 14 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 11 2 2022
Statut: ppublish

Résumé

New World hantaviruses (NWHs) are endemic in North and South America and cause hantavirus cardiopulmonary syndrome (HCPS), with a case fatality rate of up to 40%. Knowledge of the natural humoral immune response to NWH infection is limited. Here, we describe human monoclonal antibodies (mAbs) isolated from individuals previously infected with Sin Nombre virus (SNV) or Andes virus (ANDV). Most SNV-reactive antibodies show broad recognition and cross-neutralization of both New and Old World hantaviruses, while many ANDV-reactive antibodies show activity for ANDV only. mAbs ANDV-44 and SNV-53 compete for binding to a distinct site on the ANDV surface glycoprotein and show potently neutralizing activity to New and Old World hantaviruses. Four mAbs show therapeutic efficacy at clinically relevant doses in hamsters. These studies reveal a convergent and potently neutralizing human antibody response to NWHs and suggest therapeutic potential for human mAbs against HCPS.

Identifiants

DOI: 10.1016/j.celrep.2021.109086 PMID: 33951434 PMC: PMC8142553
pubmed: 33951434
pii: S2211-1247(21)00419-8
doi: 10.1016/j.celrep.2021.109086
pmc: PMC8142553
mid: NIHMS1700553
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109086

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM008320
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests J.E.C. has served as a consultant for Eli Lilly, GlaxoSmithKline, and Luna Biologics; is a member of the Scientific Advisory Boards of CompuVax and Meissa Vaccines; and is Founder of IDBiologics. The Crowe laboratory at Vanderbilt University Medical Center has received unrelated sponsored research agreements from Takeda Vaccines, IDBiologics, and AstraZeneca. Vanderbilt University has applied for patents concerning hantavirus antibodies that are related to this work. All of the other authors declare no competing interests. Opinions, interpretations, conclusions, and recommendations contained herein are those of the authors and are not necessarily endorsed by the US Department of Defense.

Références

J Virol. 1999 May;73(5):3951-9
pubmed: 10196290
J Virol. 2012 Mar;86(5):2665-75
pubmed: 22171265
Virology. 2006 Mar 30;347(1):208-16
pubmed: 16378630
J Immunol Methods. 2008 Jul 31;336(2):142-51
pubmed: 18514220
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11359-65
pubmed: 8876140
J Gen Virol. 1989 Mar;70 ( Pt 3):615-24
pubmed: 2471792
Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L379-99
pubmed: 18621912
J Virol. 2008 Feb;82(3):1332-8
pubmed: 18032485
Elife. 2019 Jun 10;8:
pubmed: 31180319
J Med Virol. 1992 Oct;38(2):132-7
pubmed: 1360999
Virology. 2005 Apr 10;334(2):319-26
pubmed: 15780882
Virology. 1993 Dec;197(2):757-66
pubmed: 7504368
J Infect Dis. 2000 Jul;182(1):43-8
pubmed: 10882580
Sci Transl Med. 2018 Nov 21;10(468):
pubmed: 30463919
Cell Rep. 2016 May 3;15(5):959-967
pubmed: 27117403
J Virol. 2003 Sep;77(18):9894-905
pubmed: 12941899
Vaccine. 2013 Sep 13;31(40):4314-21
pubmed: 23892100
Nature. 2018 Nov;563(7732):559-563
pubmed: 30464266
PLoS One. 2016 Oct 25;11(10):e0163459
pubmed: 27780250
Clin Vaccine Immunol. 2013 Feb;20(2):218-26
pubmed: 23239797
Methods Mol Biol. 2016;1442:63-76
pubmed: 27464688
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10578-83
pubmed: 10973478
Sci Transl Med. 2014 Nov 26;6(264):264ra162
pubmed: 25429055
Cell. 2020 Sep 3;182(5):1077-1092
pubmed: 32846157
J Virol. 2010 May;84(10):4889-97
pubmed: 20219926
J Med Virol. 1997 Sep;53(1):51-9
pubmed: 9298732
Nature. 2020 Aug;584(7821):353-363
pubmed: 32659783
Cell. 2015 Nov 19;163(5):1095-1107
pubmed: 26553503
J Virol Methods. 2010 Feb;163(2):416-23
pubmed: 19903496
J Gen Virol. 1996 Nov;77 ( Pt 11):2677-87
pubmed: 8922460
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
PLoS Pathog. 2020 May 4;16(5):e1008517
pubmed: 32365139
Vaccine. 2012 Mar 2;30(11):1951-8
pubmed: 22248821
Virology. 2001 Oct 10;289(1):6-14
pubmed: 11601912
Cell Rep. 2018 Dec 26;25(13):3750-3758.e4
pubmed: 30590046
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
Cell Host Microbe. 2020 Nov 11;28(5):699-711.e7
pubmed: 32783883
Virology. 2012 Feb 20;423(2):134-42
pubmed: 22209230
Clin Microbiol Infect. 2014 May;20 Suppl 5:110-7
pubmed: 24447183
Emerg Infect Dis. 2005 Dec;11(12):1848-53
pubmed: 16485469
PLoS Pathog. 2016 Oct 26;12(10):e1005813
pubmed: 27783711
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Virology. 2003 Mar 30;308(1):64-73
pubmed: 12706090
J Infect Dis. 1995 Dec;172(6):1581-4
pubmed: 7594720
mSphere. 2020 Jul 15;5(4):
pubmed: 32669473
mBio. 2020 Mar 24;11(2):
pubmed: 32209676
J Virol. 2010 May;84(9):4832-9
pubmed: 20181715
J Virol. 2001 Sep;75(18):8469-77
pubmed: 11507192
J Infect Dis. 1978 Mar;137(3):298-308
pubmed: 24670
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
Virus Res. 2014 Jul 17;187:91-6
pubmed: 24370868
PLoS Pathog. 2015 Aug 12;11(8):e1005110
pubmed: 26267277
Cell. 2020 Oct 15;183(2):442-456.e16
pubmed: 32937107
Cold Spring Harb Protoc. 2011 Jun 01;2011(6):695-715
pubmed: 21632778
Science. 2015 Jul 3;349(6243):88-91
pubmed: 26138979
Emerg Infect Dis. 2020 Apr;26(4):756-759
pubmed: 32186494
Virology. 1999 Sep 30;262(2):321-32
pubmed: 10502511
Science. 2016 Oct 21;354(6310):350-354
pubmed: 27608667
Elife. 2020 Dec 22;9:
pubmed: 33349334
Nat Protoc. 2016 Sep;11(9):1599-616
pubmed: 27490633
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
J Virol. 2007 Jul;81(14):7449-62
pubmed: 17475651
Front Microbiol. 2020 May 07;11:832
pubmed: 32508764
PLoS Pathog. 2016 Oct 26;12(10):e1005948
pubmed: 27783673
Arch Virol. 1992;122(1-2):107-18
pubmed: 1370367
Cell. 2019 May 16;177(5):1136-1152.e18
pubmed: 31100268
Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7074-9
pubmed: 9618541
Viruses. 2019 Sep 16;11(9):
pubmed: 31527500
Jpn J Med Sci Biol. 1983 Feb;36(1):17-25
pubmed: 6134854
J Clin Virol. 2015 Mar;64:128-36
pubmed: 25453325
Microbiol Spectr. 2015 Feb;3(1):AID-0027-2014
pubmed: 26104564
Nat Microbiol. 2018 Jun;3(6):670-677
pubmed: 29736037
N Engl J Med. 2020 Dec 3;383(23):2230-2241
pubmed: 33264545
Ann Soc Belg Med Trop. 1984;64(4):425-6
pubmed: 6442126
Nat Commun. 2015 Sep 29;6:8443
pubmed: 26416571

Auteurs

Taylor B Engdahl (TB)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Natalia A Kuzmina (NA)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA.

Adam J Ronk (AJ)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA.

Chad E Mire (CE)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA; Animal Resource Center, University of Texas Medical Branch, Galveston, TX 77555, USA.

Matthew A Hyde (MA)

Animal Resource Center, University of Texas Medical Branch, Galveston, TX 77555, USA.

Nurgun Kose (N)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Matthew D Josleyn (MD)

Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.

Rachel E Sutton (RE)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Apoorva Mehta (A)

Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Rachael M Wolters (RM)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

Nicole M Lloyd (NM)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA.

Francisca R Valdivieso (FR)

Programa Hantavirus, Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7590943, Chile.

Thomas G Ksiazek (TG)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA.

Jay W Hooper (JW)

Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.

Alexander Bukreyev (A)

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA. Electronic address: alexander.bukreyev@utmb.edu.

James E Crowe (JE)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: james.crowe@vumc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Broad and potently neutralizing monoclonal...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Broad and potently neutralizing monoclonal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Arvicolinae › Cricetinae › Broad and potently neutralizing monoclonal...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Bunyaviridae › Hantavirus › Broad and potently neutralizing monoclonal...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Bunyaviridae › Infections à hantavirus › Broad and potently neutralizing monoclonal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Broad and potently neutralizing monoclonal...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Broad and potently neutralizing monoclonal...